Cargando…
Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA
INTRODUCTION: US pneumococcal vaccination recommendations for adults aged 65 years or older recently changed, with options for either 20-valent pneumococcal conjugate vaccine (PCV20) or the combination of 15-valent conjugate vaccine (PCV15) followed by 23-valent polysaccharide vaccine (PPSV23) 1 yea...
Autores principales: | Smith, Kenneth J., Wateska, Angela R., Nowalk, Mary Patricia, Lin, Chyongchiou J., Harrison, Lee H., Schaffner, William, Zimmerman, Richard K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334503/ https://www.ncbi.nlm.nih.gov/pubmed/35831685 http://dx.doi.org/10.1007/s40121-022-00669-x |
Ejemplares similares
-
Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis
por: Smith, Kenneth J., et al.
Publicado: (2021) -
Cost-effectiveness of increasing vaccination in high-risk adults aged 18–64 Years: a model-based decision analysis
por: Wateska, Angela R., et al.
Publicado: (2018) -
Potential Cost-Effectiveness of a Universal Influenza Vaccine in Older Adults
por: France, Glenson, et al.
Publicado: (2018) -
The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis
por: Michaelidis, Constantinos I., et al.
Publicado: (2016) -
Differential Gene Expression Elicited by Children in Response to the 2015–2016 Live Attenuated vs. Inactivated Influenza Vaccine
por: Zimmerman, Richard, et al.
Publicado: (2017)